Minovia Therapeutics Ltd.   Report issue

For profit Phase 1
Founded: Tirat Hacarmel Israel (2011)

Organization Overview

First Clinical Trial
2018
NCT03384420
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Minovia Therapeutics Ltd.

Active Ingredients

Drugs in Phase 1 Trials (2)

cd34+ cells enriched with mnv-bld (1 trial)

mnv-bm-plc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lipid Metabolism, Inborn Errors (Phase 1)

Mitochondrial Diseases (Phase 1)

Muscular Diseases (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2